Groowe Groowe / Newsroom / SRPT
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

SRPT News

Sarepta Therapeutics,, Inc. Common Stock

Qualifacts Showcases AI Innovations, Interoperability, and Data Advancements at NatCon26

globenewswire.com
GH SRPT WLY

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

globenewswire.com
SRPT ALNY DNLI ARCT

Centri Announces Panel Topics and Featured Programming for Second Annual Capital Conference at Nasdaq on April 14

accessnewswire.com
NDAQ DFIN PTGX STRL TNDM AXSM CSTL CYTK GILD INSM KODK NBIX OCGN REGN SRPT VRTX XBIT AMZN GOOGL MSFT NVDA IBM ORGN BWEN CCJ EXC NEE SO UTL XOM BALY OXY PBF CHRD AX BAC MAXN PHIO KZR SMX DUOT COIN EHTH

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

businesswire.com
SRPT

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

businesswire.com
SRPT

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

businesswire.com
SRPT

Sarepta Provides Regulatory Update on AMONDYS 45 ® and VYONDYS 53 ®

businesswire.com
SRPT

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

businesswire.com
SRPT

Amondys 45 (casimersen: Sarepta Therapeutics) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F

globenewswire.com
SRPT

PPMD Joins Cooperative International Neuromuscular Research Group, Global Sponsors to Advance Expanded Duchenne Natural History Study

prnewswire.com
SRPT SLDB